Taurochenodeoxycholic acid, sodium salt 700249 5ß-cholanic acid-3α,7α-diol N-(2-sulphoethyl)-amide, sodium salt

Taurochenodeoxycholic Acid (TCDCA) is a taurine-conjugated form of the primary bile acid (BA) chenodeoxycholic acid (chenodiol).

Chenodiol is an epimer of ursodeoxycholic acid and has a role of a human and a mouse metabolite. It is derived in the liver as an end product of cholesterol, and it’s used as a therapeutic agent to dissolve cholesterol gallstones, at the same time.

Taurochenodeoxcholic Acid is also normally synthesized in the liver hepatocytes. Physiologically, its function is to emulsify lipids, including cholesterol, in the bile. TCDCA administration, on the other hand, leads to reduced cholesterol formation in the liver, so TCDCA in drug form is proposed to serve as a choleretic that increases the volume of bile secreted from the liver and as a cholagogue to enhance bile discharge in the duodenum.

Taurochenodeoxcholic Acid is also widely suggested to have anti-inflammatory and anti-cancerous effects, so it’s being investigated as an agent in inflammation and cancer therapy.

The taurine derivative is proven to promote monocyte differentiation, as well.

Serum concentrations of TCDCA are reported to increase in patients with liver cirrhosis, so it can serve as a marker of disease progression.

Purchase Avanti’s refined Taurochenodeoxycholic Acid research product here.